|
Sign In to gain access to subscriptions and/or personal tools.
|
Drug-induced lupus: an update
S Vasoo
Division of Rheumatology, Department of Medicine, National University Hospital, Singapore; Department of Medicine, National University Hospital, 5 Lower Kent Ridge Road, Singapore 119074, Singapore sheila_vasoo{at}nuh.com.sg
Drug-induced lupus erythematosus (DILE) is a lupus-like illness that has been recognized as an entity under environmentally-induced lupus erythematosus, where other agents such as physical (ultra-violet irradiation), chemical (heavy metals, aromatic amines) and food products (alfalfa sprouts) have been implicated. DILE has been accepted as a side effect of therapy with over 80 drugs since its first description in association with sulfadiazine in 1945. The epidemiology and clinical course of SLE and DILE differ markedly and prognosis is generally favourable in the latter although occasional lifethreatening cases have been reported in the literature. Constant pharmacovigilance is crucial for prompt diagnosis and cessation of offending therapy offers the best outcome. This review discusses the clinical presentation, diagnosis of DILE as well as provides an update on postulated pathogenic mechanisms and an overview of implicated drugs.
Key Words: drug-induced lupus erythematosus
Lupus, Vol. 15, No. 11,
757-761 (2006)
DOI: 10.1177/0961203306070000

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
D. A. Wetter and M. D. P. Davis
Lupus-Like Syndrome Attributable to Anti--Tumor Necrosis Factor {alpha} Therapy in 14 Patients During an 8-Year Period at Mayo Clinic
Mayo Clin. Proc.,
November 1, 2009;
84(11):
979 - 984.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Marzano, P Vezzoli, and C Crosti
Drug-induced lupus: an update on its dermatologic aspects
Lupus,
October 1, 2009;
18(11):
935 - 940.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
G Guhl, B Diaz-Ley, C Garcia-Garcia, J Fraga, and A Garcia-Diez
Chemotherapy-induced subacute lupus erythematosus
Lupus,
August 1, 2009;
18(9):
859 - 860.
[PDF]
|
 |
|

|
 |

|
 |
 
E. L. Williams, S. Gadola, and C. J. Edwards
Anti-TNF-induced lupus
Rheumatology,
July 1, 2009;
48(7):
716 - 720.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. C. Bockle, M. Baltaci, W. Weyrer, and N. T. Sepp
Bortezomib-Induced Lupus Erythematosus Tumidus
Oncologist,
June 1, 2009;
14(6):
637 - 639.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. A. Heyneman
Systemic Lupus Erythematosus: A Therapeutic Update
Journal of Pharmacy Practice,
February 1, 2009;
22(1):
29 - 52.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Wendt, J. Wohlrab, S. Zierz, and M. Deschauer
EFALIZUMAB-INDUCED ISOLATED CEREBRAL LUPUS-LIKE SYNDROME
Neurology,
January 6, 2009;
72(1):
96 - 97.
[Full Text]
[PDF]
|
 |
|
|
|